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Steroid hormones and their receptors have important roles in normal kidney biology, and 
alterations in their expression and function help explain the differences in development of 
kidney diseases, such as nephrotic syndrome and chronic kidney disease. The distinct 
gender difference in incidence of renal cell carcinoma (RCC), with males having almost twice 
the incidence as females globally, also suggests a role for sex hormones or their receptors in 
RCC development and progression. There was a peak in interest in evaluating the roles of 
androgen and estrogen receptors in RCC pathogenesis in the late 20th century, with some 
positive outcomes for RCC therapy that targeted estrogen receptors, especially for 
metastatic disease. Since that time, however, there have been few studies that look at use of 
steroid hormone modulators for RCC, especially in the light of new therapies such as the 
tyrosine kinase inhibitors and new immune therapies, which are having some success for 
treatment of metastatic RCC. This review summarises past and current literature and 
attempts to stimulate renewed interest in research into the steroid hormones and their 
receptors, which might be used to effect, for example, in combination with the other newer 




The incidence of kidney cancer is steadily 
increasing, and this is not only related to 
its increased diagnosis from abdominal 
imaging which is used frequently in today’s 
diagnostic medicine, but also to a real 
increase in kidney cancer incidence. Kidney 
cancers are the second most-commonly 
diagnosed urologic malignancy in Australia 
behind prostate cancer. Ninety-two percent 
of kidney cancers are renal cell carcinoma 
(RCC). Contrasting with prostate cancer, in 
2010 there were 3,235 deaths from 
prostate cancer and 927 deaths from 
kidney cancer in Australia (1). Thus the  
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Figure 1. Comparison of incidence and deaths in prostate versus kidney cancer per annum in 
Australia in 2010. In 2010 there were 3,235 deaths from prostate cancer and 927 deaths from 
kidney cancer in Australia (1). The comparable incidence of the cancers is 30% of all males having 
prostate cancer diagnoses, versus kidney cancer at approximately 2.4% of a population. This indicates 
that kidney cancer deaths are almost double what could be expected by simply extrapolating from 
cancer incidence and prostate cancer deaths. 
 
annual deaths from prostate cancer are 
approximately 3.5 times kidney cancer 
deaths. The comparable incidence of the 
cancers, however, at 30% of all males 
having prostate cancer diagnoses, versus 
kidney cancer at approximately 2.4% of a 
population, indicates the deaths from each 
cancer is disproportional (Figure 1) with 
kidney cancer deaths almost double what 
could be expected extrapolating simply 
from prostate cancer incidence and deaths. 
Continuing this comparison, the 5-year 
overall survival of patients with prostate 
cancer is 92% whereas for kidney cancer is 
71.9%. RCC are also highly metastatic, 
with approximately 25-30% of RCC 
patients having metastases at presentation, 
and 40% to 50% developing metastases 
after the primary treatment. The 5-year 
survival of patients with metastatic disease 
is less than 10%. However, despite its 
lethality compared with incidence, and 
poor long-term survival, kidney cancer has 
not yet attracted the same level of public 
health attention and research funding as 
other cancers, such as prostate cancer. The 
outlook for patients with RCC, especially 
metastatic RCC, continues to be poor.  
 
RCC consists of three major subtypes (clear  
cell RCC at 70-80% incidence; papillary 
RCC at 10-15% incidence; chromophobe 
RCC at 5% incidence) (2). RCC lethality 
undoubtedly develops because of late 
detection of the cancer and clever kidney 
compensatory mechanisms. As shown in 
the tumour (T) staging of kidney tumours 
in the tumour-node-metastasis (TNM) 
system (Table 1), stage T1 kidney tumours, 
considered (apart from T0) least dangerous 
in tumour staging of renal growths, can be 
up to 7cm across (T1a up to 4cm, T1b from 
4 to 7cm) (3) within this staging. These 
relatively large masses are often detected 
incidentally as part of abdominal imaging. 
Why would a 7cm mass not be detected via 
loss of renal function or development of 
pain? The kidneys have a great propensity 
to compensate for, and mask, focal loss of 
renal function. General loin pain, typical of 
RCC presence, is non-informative as to the 
source. In addition, loin pain, loin mass 
and frank haematuria present in less than 
30% RCC patients. The late RCC detection 
then produces some intrinsic problems. 
The greater the renal mass, the more likely 
that the cancer may invade locally or 
metastasise to another part of the body. 
Surgical resection of the primary tumour is 
broadly touted as successful as a curative  
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Table 1. Tumour (T) stages of kidney cancer in the TNM system of classification 
T0 No evidence of a primary tumour in the kidney 
T1 
Tumour is no more than 7cm across and is completely inside the kidney (T1a 
indicates the tumour is equal to or less than 4cm across; T1b indicates a tumour of 
4 to 7cm across) 
T2 The tumour is more than 7cm across, but is still completely inside the kidney 
T3 
The cancer has spread through the outer covering of the kidney (the capsule), to a 
major vein, the adrenal gland or other tissues around the kidney 
T4 The cancer has spread further than the tissues around the kidney 
 
 
treatment, but is the frequent metastases 
that are dangerous, with approximately 
50% of patients eventually developing 
metastatic RCC (4). Although there is some 
progress, there are currently no clinically-
proven adjuvant therapies that exist for 
RCC patients at high risk of relapse 
following surgical resection, and treatment 
of the metastases is generally unsuccessful 
in the long term. This cancer also exhibits 
resistance to chemotherapy and radiation, 
and less than 10% of patients suffering 
from metastatic disease survive 5 years 
after diagnosis.  
 
Some clinical observations such as the 
significant sex differences of RCC (twice as 
common in men as in women) (5,6), its 
variation with the cessation of gonadal 
activity, and the regression of metastatic 
kidney cancer during administration of 
progestin or androgen (greater in men than 
in women) has led to the hypothesis that 
some human kidney cancers are hormone-
dependent (7). The exact nature of the role 
of hormones and their receptors in RCC 
development has yet to be clearly defined. 
A better understanding of the molecular 
pathways that determine development and 
progression of RCC is needed. Further 
investigations into steroid hormone 
pathobiology in RCC will greatly enhance 
our understanding of why kidney cancers 
grow and thrive, and just as importantly, 
resist therapies. This mini review updates 
information on the role of steroid hormones 
in kidney cancer and their possible 
modulation as a treatment, especially for 
metastatic disease. 
 
Steroid hormones and RCC 
 
Steroid hormones and their receptors have 
 an important role in normal kidney 
biology. The mineralocorticoid aldosterone, 
of the renin-angiotensin-aldosterone 
system (RAAS), is probably best known of 
the steroid hormones in kidney biology (8). 
The RAAS is necessary for early and late 
stages of kidney development. Aldosterone 
is endogenously secreted to maintain the 
RAAS. This hormone is, however, 
pathogenic when dysregulated. Aldosterone 
acts at the mineralocorticoid receptor (9). 
When the steroid is dysregulated, it is best 
known for its contribution to the 
development and progression of 
cardiovascular and renal disease. There is 
little direct evidence for dysregulation of 
the RAAS in RCC development and any 
links are at best suggestive, but the links 
to lipid biosynthesis, cholesterol 
metabolism and, consequently, to 
aldosterone support an association with 
clear cell RCC (ccRCC), which form the 
majority of kidney cancers. ccRCC are 
characterized by the accumulation of 
cholesterol, cholesterol esters, other 
neutral lipids and glycogen. One clue to 
this relationship has come from the 
elucidation of the hereditary kidney cancer 
gene, TRC8, which functions partly to 
degrade key regulators of endogenous 
cholesterol and lipid biosynthesis, thereby 
contributing to the changes that are typical 
of ccRCC. Yakirevich et al (9) have also 
shown that mineralocorticoid receptors are 
upregulated in the distal tubular 
epithelium during kidney cancer 
development. The distal tubular epithelium 
is the site of origin of chromophobe RCC 
and perhaps oncocytoma, two of the renal 
neoplasms with low incidence. 
  
In addition to these studies, other 
epidemiological studies have found higher 
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cancer mortality in hypertensive patients. 
One established risk factor for development 
of RCC is hypertension (5). Mortality is 
particularly elevated in hypertension 
associated with a stimulation of the RAAS. 
This may relate to angiotensin II being 
genotoxic due to its induction of oxidative 
stress, but aldosterone also has oxidative 
effects that could contribute to DNA 
damage and mutations (10). In kidney 
cancer cell culture experiments, 
aldosterone concentrations starting from 
10nM caused a significant increase in DNA 
damage and the formation of micronuclei. 
Addition of the steroidal mineralocorticoid 
receptor antagonist spironolactone reduced 
the DNA damage and superoxide radicals, 
indicating a receptor-dependent process. 
Thus one of the most common pathways in 
kidney metabolism could potentially 
contribute to the sporadic development of 
RCC. Because of its broad role in our 
general metabolism, it is unlikely to be 
successful as a target for therapy.  
 
Other steroid receptors are glucocorticoid 
receptor, progesterone receptor, androgen 
receptor (AR), estrogen receptor (ER), 
vitamin D receptor, and retinoic acid or 
retinoid X receptors (RAR, RXR). These 
receptors have important roles in growth 
and differentiation in neoplastic and non-
neoplastic states. They act as ligand-
dependent transcription factors, but there 
is growing evidence that these receptors 
can also induce gene expression through 
ligand-independent pathways (11). All have 
some recorded role in normal kidney 
growth and RCC development (12), 
although often the differential expression in 
RCC appears to be functionally-
insignificant, because modulation of the 
receptors produces little therapy benefit to 
stop growth of RCC. In this mini review, we 
will concentrate on AR, ER, and the 
retinoid receptors. 
 
Androgen receptor in RCC 
 
Androgens, such as testosterone, are 
hormones that are important for normal 
male sexual development before birth, 
during puberty, and maintenance of the 
male phenotype during adulthood. 
Androgen binding to AR results in the 
formation of an AR transcription-regulatory 
complex, whereby AR binds directly to DNA 
and regulates the activity of androgen-
responsive genes (13). Androgens and AR 
have important functions in males, such as 
development of male-specific phenotypes 
during embryogenesis, spermatogenesis, 
sexual behaviour, and fertility during adult 
life, and also in females, such as 
development of female reproductive organs 
and their functions (ovarian 
folliculogenesis, embryonic implantation, 
and uterine and breast development) (14). 
The effects of androgens on kidney cancer 
development and growth have engendered 
interest for decades, and may be mediated 
through modulation of AR. However, there 
is also a close link between AR activity, 
transcription of specific cytokines and 
growth factor, and stimulation of their 
receptors, and these may also be targets for 
therapy in AR modulation. A deeper, 
improved, knowledge of the interaction 
between sex hormones and progression of 
kidney cancer is important, as use of 
selective steroid receptor modulators may 
yet represent a therapeutic option for 
patients with kidney cancer.  
 
Epidemiological studies indicate that RCC 
has a gender difference in tumour 
incidence (male-to-female ratio 1.6:1) (15). 
The gender difference in RCC susceptibility 
is one of the most consistent findings in 
kidney cancer epidemiology. Early studies 
suggest that many types of diseases with 
incidence of gender difference might be 
linked to steroid hormone receptor 
expression and function. Examples include 
hematologic malignancies, and 
autoimmunity diseases more commonly 
found in women. However, early studies on 
the linkage between AR expression and 
RCC progression have produced 
controversial findings (12). The early 
studies often did not differentiate AR 
expression in different RCC subtypes, and 
AR function was often disregarded. More 
recently, however, Zhu et al (7) investigated 
the expression of AR in patients with RCC 
with different clinical stages and pathologic 
grades. They also explored the function of 
AR using human RCC cells in culture. The 
expression of AR was detected by 
immunohistochemistry in 44 adjacent 
normal kidney tissues of nephrectomies 
from 120 RCC patients and also in 16 
metastatic RCC patients with their 
respective primary and metastatic tissue 
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samples. In commonly used human RCC 
cell lines and normal kidney epithelial cells, 
expression of AR was assessed by Western 
blot, as well as transcriptional activity by 
luciferase assay in those AR-positive RCC 
cells. The expression rate of AR was higher 
in adjacent normal kidney than in RCC 
tissues, and it was negatively associated 
with tumour stage and Fuhrman's grade. 
Specifically, there were 40.7% AR-positive 
cases in T1 compared with 8.0% in T3 
(p=0.013), and 50.0% of grade I cases were 
found to be AR positive compared with 
12.9% in grade III (p=0.008). AR expression 
was slightly higher in primary RCC tissues 
(12.5%) than their respective metastases 
(0%, p=0.484). Although lacking 
significance, the lack of AR-positive cases 
in the metastatic counterparts of the 
tumour samples may indicate that once 
RCC metastasize from their primary site, 
their AR expression level becomes even 
lower. There was no significant difference of 
AR-positivity between male and female 
patients in RCC or adjacent normal kidney 
tissue samples. AR strongly expressed in 
CaKi-2 and OSRC-2 RCC cells in culture, 
but with little transactivation, which might 
indicate functionally-inactive AR in those 2 
RCC cell lines. These results demonstrate 
that, although a very heterogeneous 
cancer, there is a population of RCC 
patients in which AR might be targeted for 
therapy. However, more importantly, the 
results also indicate the need for further 
examination of AR function in RCC, to 
make a correct correlation between AR and 
RCC progression. 
 
Other studies provide disparate results. A 
relatively high rate of AR expression (5 in 
12 primary RCC and 1 in 5 metastatic 
RCC) was recorded (16). In contrast, other 
studies found: few cases that were AR-
positive (17) (compared with, for example, 
AR expression in prostate cancer); AR 
expression in 3 of 21 RCC (18); and AR 
expression in 13 of 41 RCC cases (19). 
Langner et al (20) produced a systematic 
study that demonstrated AR in almost 27 
of 182 of RCC cases (15% of the tumours). 
AR expression was significantly associated 
with low stage, well or moderately 
differentiated tumours, and a favourable 
outcome, decreasing with tumour growth 
and dedifferentiation. Although this study 
provided some important information about 
AR in RCC progression, similar to Zhu et al 
(7), it did not show AR differences between 
normal kidney and RCC, between primary 
RCC and metastasis, and between male 
and female RCC patients.  
 
Estrogen receptor and RCC – including 
studies of tamoxifen therapy 
 
Female sex is generally associated with a 
better clinical outcome in kidney diseases 
(6) and the incidence of RCC in females is 
much lower than in males. Female 
hormones, such as estrogen, may play 
important roles in protecting females 
against kidney disease, including during 
RCC carcinogenesis, thereby accounting for 
the different incidence rates between males 
and females. The initial experiments 
describing differences in ER in RCC versus 
normal kidney, and in male versus female 
RCC, were carried out in the early 1980s 
(21-23). More recently, Yu et al (24) 
investigated ER in RCC compared with 
breast cancer cell lines. They found that 
ERβ was more highly expressed in RCC cell 
lines (A498, RCC-1, 786-O, ACHN, and 
CaKi-1) than in breast cancer cell lines 
(MCF-7 and HBL-100); however, they 
detected no AR or ERα by Western blot. 
They also reported that estrogen-activated 
ERβ acted as a tumour suppressor, 
decreasing cell proliferation and increasing 
apoptosis. Proliferation of RCC cell lines 
was significantly decreased after estrogen 
(17-β-estradiol) treatment. They suggested 
(i) that these results may explain the 
different RCC incidence rates between 
males and females; and (ii) that ERβ might 
be a useful prognostic marker for RCC 
progression and a novel developmental 
direction for improvements in RCC 
treatment. 
 
The links with ER in RCC were also utilized 
when tamoxifen therapy became available 
as a common treatment for ER-positive 
breast cancer, and was applied in RCC 
patients as well. The outcome in RCC 
patients was disparate. Most studies were 
carried out in the 1990s. In a study by 
Papac and Keohane (25), 34 patients with 
progressive advanced RCC were treated 
with high-dose tamoxifen (100 mg/m2 
daily) until progression. The overall 
remission rate was 12%, including 1 
complete remission. Seventeen of these 
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patients (50%) had minor remission or no 
change. Taking into consideration the 
documented progression prior to tamoxifen, 
further tumour growth could be arrested in 
62% of the patients, with a one-year 
survival rate of 41%. Patients with only 
pulmonary metastases, good performance 
status and prior nephrectomy seemed to 
have a better survival. Side effects were 
comparable to those of conventional doses 
of tamoxifen (20-30 mg/m2 daily). These 
data suggested that high dose tamoxifen 
may be a useful therapeutic approach with 
low toxicity, especially in metastatic RCC 
that has few treatment options.  
 
Henricksson et al. (26) compared 
interleukin 2/interferon-alpha (IL-2/IFN-
alpha) and tamoxifen, with a control arm of 
tamoxifen only, in RCC patients. Tamoxifen 
had been shown to potentiate in vivo anti-
tumour activity of IL-2, and because of its 
non-toxic behaviour it was included in the 
therapy groups. The final survival analysis 
showed no significant differences between 
the two treatment arms in comparing 
patients from the day of diagnosis of 
primary disease, from the day of first 
evidence of metastatic spread, or from the 
onset of treatment.  
 
In another phase II study (25), the 
effectiveness of hormonal therapy using 
combined high dose androgen and provera 
or tamoxifen, in patients with advanced 
RCC, was studied. 30 patients with 
metastatic RCC received testosterone 
propionate (100 mg intramuscularly/i.m.) 5 
times weekly plus provera (400 mg, i.m.) 
twice weekly until disease progression 
developed. Twenty patients, who had 
previously failed to respond to androgen 
and provera, received tamoxifen (100 
mg/m2 daily). Of the 30 patients treated 
with androgen and provera, 3 developed 
partial responses of brief duration; 2 of 20 
patients experienced tumour response with 
tamoxifen, with one instance of complete 
disappearance of pulmonary metastases, 
and another case demonstrating disease 
stability.  
 
Thus, while combined hormonal therapy 
offered little therapeutic advantage in 
advanced RCC, tamoxifen in high dose 
exerted some anti-tumour effects in a small 
number of cases. 
Retinoids 
 
The processes of tissue injury and repair in 
renal disease do not depend on the action 
of single genes but involve a complex 
network of growth factors and cytokines. In 
this context, retinoids, which are steroidal 
derivatives of vitamin A, have attracted 
attention as potential therapeutic agents 
(27). Retinoids modulate the function of 
several key transcription factors which are 
involved in mechanisms that are operative 
in renal diseases including kidney cancers. 
The link between retinoids and steroids 
had not been appreciated until the retinoid 
receptors were discovered. Retinoic acid 
receptors (RAR) belong to a gene family of 
ligand‐inducible transcriptional regulatory 
factors that includes steroid hormone, 
thyroid hormone, and vitamin D3 
receptors, as well as the peroxisome 
proliferator activated receptors. The RAR 
and the retinoid X receptors (RXR) can be 
subdivided into isotypes ‐α, ‐β, and ‐γ. 
These subtypes are expressed in a tissue‐ 
and developmental stage‐specific pattern. 
RARα is the most widely expressed retinoid 
receptor isotype. In the kidney, both RAR 
and RXR are cell‐specifically expressed. 
The kidney is, therefore, potentially 
responsive to activation of both receptors 
by their respective agonists. Double knock‐
out mouse models (both RAR and RXR 
deleted) have several renal malformations 
that include agenesis, hypoplasia, or 
aplasia of the ureteral bud. There are few 
studies, however, that look at these 
receptors as potential causes of cancer 
development and targets for RCC therapy. 
 
Most abnormalities in retinoid receptors 
have been found in RAR-α and RAR-β (28). 
Point mutations in RAR-α were reported for 
some cancer cells in culture but it is not 
clear whether these occur spontaneously in 
cancers in patients, or as a result of 
resistance to treatment with retinoic acid. 
The mechanisms responsible for RAR-β 
alterations are not well-described but may 
occur as a pre-malignant change. Again, 
many of the investigations have been 
carried out in vitro, but DNA extracted 
from paraffin sections of tumours indicated 
loss of RAR-β in tumour samples. RAR-β 
expression may depend in the cellular level 
of retinoids as this receptor is inducible by 
retinoids. Thus, vitamin A deficiency may 
Gobe, G et al.                                                                                                                          Steroid hormones in RCC 
 
JKCVHL 2014;1(2):17-25  http://jkcvhl.com  23 
 
have a secondary effect of lowering 
expression of RAR-β. RAR-β mRNA was not 
found to be expressed by retinoid-resistant 
RCC cell lines but was present in a 
retinoid-sensitive renal cancer cell (SK-RC-
06) and increased following incubation with 
retinoic acid. At least for RCC, this 
suggested that the antitumour action of RA 
was mediated through RAR-β (29). Berg et 
al (30) extended this study with a patient 
cohort. They found RAR-β transcripts 
increased in tumour cells of RCC patients 
who clinically responded to retinoid-based 
therapy, and suggested that retinoids that 
potently induce RAR-β expression should 
be evaluated in the treatment of advanced 
RCC.  
 
In other similar early studies on the 
benefits, or otherwise, of retinoic acid 
therapies, Motzer et al. (31) applied their 
knowledge of changes in retinoid receptors 
in kidney cancers to carry out a phase II 
trial of IFN-2a and 13-cis-retinoic acid 
(CRA) in patients with RCC. They also 
performed in vitro studies to investigate 
potential mechanisms of interaction. IFN-
2a was given daily at 3 million units (MU) 
and escalated to 6 and 9MU if tolerated. 
CRA was given at 1 mg/kg/d. Thirteen of 
43 assessable patients achieved complete 
[3] and partial [10] responses at sites 
including bone metastases and renal 
primary tumours. Seven responding 
patients remained progression-free at 10 to 
19 months post-therapy. The response 
proportion was higher than with IFN-2a 
alone, which was 10% in 149 patients. 
Thus, IFN-2a and CRA showed anti-tumour 
activity in patients with advanced RCC, 
and the proportion and nature of response 
suggested CRA added therapeutic benefit to 
IFN.  
 
This same group progressed to a 
randomized phase III trial of IFN-2a with 
and without CRA (32). 284 patients were 
randomized to treatments. IFN-2a was 
given daily subcutaneously, starting at a 
dose of 3MU and escalated every 7 days 
from 3 to 9MU (by increments of 3MU), if 
toxicity was tolerated. Patients randomized 
to combination therapy were given oral 13-
CRA 1 mg/kg/d plus IFN-2a. Complete or 
partial responses were achieved by 12% of 
patients treated with IFN2a plus CRA and 
6% of patients treated with IFN2a (p=0.14). 
Median duration of response (complete and 
partial combined) in the group treated with 
the combination was 33 months (range, 9 
to 50 months), versus 22 months (range, 5 
to 38 months) for the second group 
(p=0.03). 19% of patients treated with 
IFN2a plus CRA were progression-free at 
24 months, compared with 10% of patients 
treated with IFN2a alone (p=0.05). There 
was no difference in survival between the 
two treatment arms (p=0.26). Treatment, 
particularly the combination therapy, was 
unfortunately associated with decreased 
quality of life because of the toxicities of 
both IFN and CRA, and these trials have 
not progressed. 
 
While the use of retinoic acid has not been 
taken up generally in RCC therapies, 
studies point to the use of the receptors, 
particularly RAR-β, as biomarkers for 
clinical response to therapy with retinoic 
acid. This work was originally carried out 
in pre-malignant oral lesions and cancers 
of the oral cavity (33). The expression of 
RAR-β mRNA was selectively lost in 
premalignant oral lesions and could be 
restored by treatment with isotretinoin. 
Restoration of the expression of RAR-β 
mRNA was associated with a positive 
clinical response, and the restoration may 
have a role in mediating the response to 
retinoids. Thus, RAR-β was a useful 
intermediate biological marker in trials of 
these agents for the prevention of oral 
carcinogenesis. Similar investigations in 




Kidney cancers such as RCC are not given 
the research priority they deserve. At 2-3% 
of all cancers, kidney cancer is seen as 
having low incidence. The 5-year survival of 
RCC patients with metastatic disease, 
however, is less than 10%. It seems likely 
that the promotion of research into other 
more common cancers such as breast, 
prostate, skin, and head and neck cancers 
has overshadowed the need for financial 
support for kidney cancer research, and 
this is now being reflected in the limited 
number of publications on such 
potentially-important aspects of RCC 
development and progression, as the role of 
steroid hormones and their receptors. 
Further investigations into steroid hormone 
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pathobiology in RCC may greatly enhance 
our understanding of why kidney cancers 
grow and thrive, and just as importantly, 
resist therapies. RCC are highly 
heterogeneous, therefore expression 
patterns of any molecules (biomarkers), 
and response to therapy, need to be 
interpreted in terms of such heterogeneity 
of RCC. This review has attempted to 
stimulate renewed interest in research into 
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